Trainee’s Projects
- Matthew Moccia, MD: Epigenetic therapy for pancreatic neuroendocrine tumor (PNET)
- Hansa Joshi, MD: Identification of Molecular Pathways Associated with Non-Small Cell Lung Cancer Subtype Switching after Treatment
- Yazid Khalil Mo Ghanem, MD: Intraperitoneal epigenetic drug perfusion for colon cancer-associated peritoneal carcinomatosis
- Helen Toma, MD: Chemotherapy Resistance in Ovarian Cancer and the Role of NRF2
- Zena Saleh, MD: Epigenetic alterations are associated with gene silencing and immune infiltration in human PNET
- Zachary Ladd, BS: Development of novel NRF2 inhibitors
Faculty/Staff Projects
- Tao Gao, PhD: Chemo- and radio-sensitization of NRF2Mut cancer with molecular glue
- Weam Elbezanti, PharmB, MS, PhD:
- Epigenetic treatments and their effects on tumor microenvironment
- Intraperitoneal epigenetic drug perfusion for colon cancer-associated peritoneal carcinomatosis
- The effect of histotripsy on immune activation and cancer eradication
- Samera Hamad, PhD:
- The Role of NRF2 in the Development of Lung Cancer Subtypes.
- Identification of Molecular Pathways Associated with Non-Small Cell Lung Cancer Subtype Switching after Treatment.
- Chemotherapy Resistance in Ovarian Cancer and The Role of NRF2.
- Boopathi Subramaniyan, M.Phil, PhD: NRF2-responsive kinase in esophageal squamous cell carcinoma
- Huan Li, PhD: Chemo- and radio-sensitization of cancer cells
- Yahui Li, MS: Lymphatic metastasis of esophageal squamous cell carcinoma
- Xiaoxin Luke Chen, MD, PhD: NRF2 in esophageal squamous cell carcinoma and alcohol-associated esophageal pathology
- Young Hong, MD:
- Epigenetic therapy for pancreatic neuroendocrine tumor (PNET)
- HIPEC with epigenetic drugs for peritoneal carcinomatosis of colorectal cancer
- Francis Spitz, MD:
- NRF2 activation in lung and head & neck cancer